The latest Endpoints 100 survey reveals the most negative sentiment among biotech and pharma executives in its history. This 'winter of discontent' is driven by a market downturn that has now lasted three years, far longer than anticipated, with no clear end in sight.
Access to capital is a primary concern, with a record number of executives rating VC funding as poor and zero rating it as excellent. Investors are concentrating capital on a smaller number of portfolio companies, leading to a drop in mega-rounds and making it exceptionally difficult for early-stage or struggling companies to raise funds.
The new political administration has introduced significant anxiety regarding the future of the FDA and science-based policy. Executives overwhelmingly disapprove of leadership changes at CIBER and anticipate that the FDA's reorganization will have a harmful effect on the industry, potentially causing drug approval delays.
The prolonged downturn is forcing a change in mindset from the industry's traditional 'nine lives' approach. Boards are now making faster, more decisive calls to wind down operations when strategic alternatives fail, as exemplified by Ikena Oncology's rapid shutdown.
Keep pulling the thread on Endpoints 100.